Alimta and Vaginal bleeding - a phase IV clinical study of FDA data

Summary:

Vaginal bleeding is reported as a side effect among people who take Alimta (pemetrexed disodium), especially for people who are 30-39 old, have been taking the drug for 1 - 6 months also take Cisplatin, and have Cervix carcinoma recurrent.

The phase IV clinical study analyzes which people have Vaginal bleeding when taking Alimta. It is created by eHealthMe based on reports of 7,644 people who have side effects when taking Alimta from the FDA, and is updated regularly.

What is Alimta?

Alimta has active ingredients of pemetrexed disodium. eHealthMe is studying from 7,702 Alimta users. Check the latest studies of Alimta.

What is Vaginal bleeding?

Vaginal bleeding is found to be associated with 1,128 drugs and 1,539 conditions by eHealthMe. Check the latest studies of Vaginal bleeding.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

7,644 people reported to have side effects when taking Alimta.
Among them, 15 people (0.2%) have Vaginal bleeding.

Among these 15 people:

How long have people been on Alimta when they have Vaginal bleeding? *

What is the age of people who have Vaginal bleeding when taking Alimta? *

What are other drugs people take besides Alimta? *

What are other side effects people have besides Vaginal bleeding? *

Thrombocytopenia (decrease of platelets in blood): 6 people, 40.00%
Vision Blurred: 5 people, 33.33%
White Blood Cell Count Decreased: 4 people, 26.67%
Anaemia (lack of blood): 4 people, 26.67%
Haemoglobin Decreased: 3 people, 20.00%
Infection: 3 people, 20.00%
Tumor: 2 people, 13.33%
Back Pain: 2 people, 13.33%
Urinary Tract Infection: 2 people, 13.33%
Acute Kidney Failure: 2 people, 13.33%

What are the existing conditions these people have? *

Non-Small Cell Lung Cancer Stage Iiib: 1 person, 6.67%
Neoplasm Malignant (cancer tumour): 1 person, 6.67%
Nasopharyngeal Cancer (cancer of nasopharynx): 1 person, 6.67%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 6.67%
Lung Carcinoma Cell Type Unspecified Stage 0 (the lung cancer has not spread beyond the inner lining of the lung): 1 person, 6.67%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 6.67%
Lung Adenocarcinoma Stage Iv (the cancer has spread to other organs of the body, such as the other lung, brain, or liver): 1 person, 6.67%
Insomnia (sleeplessness): 1 person, 6.67%
Depression: 1 person, 6.67%
Cervix Carcinoma Recurrent (repeated cancer of cervix): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Alimta and have Vaginal bleeding?

- Check whether Vaginal bleeding is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Alimta:

Alimta (7,702 reports)

Vaginal bleeding treatments and more:

Vaginal bleeding (49,485 reports)

Browse all side effects of Alimta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Vaginal bleeding:

Vaginal bleeding (1,128 drugs)

Browse all the conditions that are associated with Vaginal bleeding:

Vaginal bleeding (1,539 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pemetrexed disodium (the active ingredients of Alimta) and Alimta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.